

September 16, 2003

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Applicants: Thomas Freeman et al.

Serial No.: 10/604,591 Filing Date: 08/01/2003

For: Method of Treating Herpes Virus Infections

Our Reference No.: 1372.50

Examiner: Unassigned Art Unit: Unassigned

Dear Sir:

Enclosed please find the following:

1. Information Disclosure Statement By Applicants- 2 pages;

2. Copies of three (3) U.S. Patent Documents;

3. Copies of seventeen (17) Non-Patent Literature Documents; and

4. Self-addressed, postage-prepaid postcard to serve as a receipt for items 1-3.

Very respectfully,

By: Anton J. Hopen

anton.hopen@baypatents.com

AJH/sb enclosure

## CERTIFICATE OF MAILING (37 C.F.R. 1.8)

I HEREBY CERTIFY that this correspondence is being mailed with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on September 16, 2003.

Date: September 16, 2003

Shelley Butry

Attorney-Client Privileged Communication

				. 1	
Please type a	plus sign (	<ul><li>+) inside</li></ul>	this box	→	+

PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE of information unless it contains a wait OMB and the contains a wait of OMB and the contains a wait o

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of

Co	omplete if Known
Application Number	10/604,591
Filing Date	08/01/2003
First Named Inventor	Thomas Freeman et al.
Group Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	1372.50

U.S. PATENT DOCUMENTS						
Cite No.1	U.S. Patent		Name of Patentee or Applicant	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
1	4,415,590		Gerzon			
2	6,174,916		McMichael			
3	4,657,761		Pinto			
		<del>_</del>				
	<u> </u>					
	No. <sup>1</sup> 1 2	Cite No.1 Number 1 4,415,590 2 6,174,916	No.1 Number (if known)  1 4,415,590  2 6,174,916	U.S. Patent Document   Name of Patentee or Applicant of Cited Document	Cite No.1         Number         Kind Code (if known)         Name of Patentee of Applicant of Cited Document         Cited Document MM-DD-YYYY           1         4,415,590         Gerzon           2         6,174,916         McMichael	

				FORE	IGN PATENT DOCUMEN	rs		
	011-	F	oreign Patent Do	cument	Name of Patentee or	Date of Publication of	Pages, Columns, Lines, Where Relevant	
Examiner Initials	Cite No. <sup>1</sup>	Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> ( <i>if known</i> )	Applicant of Cited Document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear	T <sup>6</sup>
								<del> </del>
								—
								—
								╆
	_		<del></del>					+
		_			<del> </del>			+-
		<del> </del>				<del>                                     </del>		+
<u> </u>		<del>                                     </del>			· · · · · · · · · · · · · · · · · · ·	1		$\vdash$
		<del>                                     </del>		<del></del>		<del> </del>		$\top$

Examiner	Date	
LXAIIIIICI	Canaidarad	
Signature	Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

SEP 2 2 2003

Release type a plus son (+) inside this box -> +

Sheet

3

PTO/SB/08B (10-96)

Approved for use through 10/31/99. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complet if Kn wn

Application Number 10/604,591

Filing Date 08/01/2003

First Named Inventor Thomas Freeman et al.

Group Art Unit Unassigned

Examiner Name Unassigned

Attorney Docket Number 1372.50

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) Application Number Filing Date First Named Inventor Group Art Unit Examiner Name

of

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the Examiner T2 item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), Initials No. publisher, city and/or country where published. LANGEVIN ET AL.; Rabies Virus Glycoprotein (RVG) is a Trimeric Ligand for the N -Terminal Cysteine-rich Domain of the Mammalian p75 Neurotrophin Receptor; Journal of Biological; THOMAS FREEMAN; The Prospects for Vaccination Against Herpes Viruses; Power Point 5 Presentation: 2001 Herpesvirus Replication; http://darwin.bio.uci.edu/~faculty/wager/movietext.himl; 9/5/2001 6 EISENBERG, Ph.D.; University of Pennsylvania School of Veterinary Medicine; 9/5/2001 FERSON; Varicella Vaccine in Post-Exposure Prophylaxis; 8 http://health.gov.au/pubhlth/cdi2501/cdi2501e.htm; 9/5/2001 KUTER ET AL.: Efficacy of OKA/Merck Varicella Vaccine After Concomitant Administration with 9 M-M-R II: 9/5/2001 Varicella Virus Vaccine Live (Oka/Merch); www.geocities.com/mom2q/CPVaccineInsert.htm; 10 9/5/2001 Facts About Shingles )Varicella-Zoster Virus); www.niaid.nih.gov/factsheetsFS.htm; 9/5/2001 EHRMAN; A Potential Shingles Vaccine; www.nih.gov/news/WordonHealth/oct2000/story03.htm; 12 10/2000 History of Rabies; http://justice.loyola.edu/~klc/BL472/Rabies/rabies~1.htm 13 MASCOLA; Herpes Simplex Virus Vaccines - WHy Don't Antibodies Protect?; http://jama.ama.assn.org/issues/v282n4/ffull/jed90053.html; Vol 282, No. 4; 7/28/1999 14

Examiner	Date	
Signature	Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

1	<b>2</b> /
CCD 2 2 2003	<u>w</u>
1 30, 4	<b>]</b>
Please type a	is sign (+) inside this box -> +
The man of	

Substitute for form 1449B/PTO

Sheet

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

of

PTO/SB/08B (10-96)

Please type and s sign (+) inside this box 

+ 

Approved for use through 10/31/99. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Co	Complete if Kn wn			
Application Number	10/604,591			
Filing Date	08/01/2003			
First Named Inventor	Thomas Freeman et al.			
Group Art Unit	Unassigned			
Examiner Name	Unassigned			
Attorney Docket Number	1372 50			

		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the	
Examiner Initials*	Cite No. <sup>1</sup>	item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
·——	15	COREY ET AL.; Recombinant Glycoprotein Vaccine for the Prevention of Genital HSV-2 Infection; American Medical Association; 7/28/1999; Vol. 282, No. 4, pg.331-340	
	16	The Big Picture Book of Viruses: Herpesviridae; www.virology.net/Big_Virology/BVDNAherpes.html; 9/5/2001	
	17	Virus Antigens; www.virotest.com/products3_e.htm; 9/5/2001	
	18	IMOGAM Rabies Pasteurized [Rabies Immune Globulin, Pasteurized (Human)];	
	19	SHERMAN, R.Ph.D.; Rabies: A History and Update on Prophylaxis Regimens in the U.S.; www.uspharmacist.com/NewLook/DisplayArticle.cfm?item_num=563; 11/26/2001	
	20	IMOVAX Rabies [Rabies Vaccine Inactivated (DCO)]	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Date Considered

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

+

Examiner

Signature

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.